TuHURA Biosciences (NASDAQ:HURA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences (NASDAQ:HURA) from a sell rating to a hold rating in a report issued on Wednesday.

Several other equities research analysts have also recently commented on HURA. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, TuHURA Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Trading Down 1.4%

Shares of NASDAQ HURA opened at $2.92 on Wednesday. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.44. The stock has a 50 day moving average of $1.76 and a two-hundred day moving average of $1.62. The stock has a market cap of $185.65 million, a P/E ratio of -4.63 and a beta of -0.32.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Trading of TuHURA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HURA. Virtu Financial LLC purchased a new stake in TuHURA Biosciences in the 3rd quarter worth approximately $26,000. JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences in the 2nd quarter valued at about $27,000. Wells Fargo & Company MN grew its holdings in TuHURA Biosciences by 109.0% in the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after buying an additional 19,931 shares during the period. Goldman Sachs Group Inc. purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $30,000. Finally, Invesco Ltd. purchased a new stake in TuHURA Biosciences in the 2nd quarter valued at about $30,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.